🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT07727135
Starting soon Not applicable

Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation

NCT07727135 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-06

Condition(s) studied

Coronary Syndrome, AcuteMyocardial InfarctionCoronary Artery DiseaseCardiovascular DiseasesCardiovascular Disease Acute

Investigational drug(s) / intervention(s)

0/3-hour high-sensitivity cardiac troponin algorithm0/1-hour high-sensitivity cardiac troponin algorithm

0/3-hour high-sensitivity cardiac troponin algorithm: High-sensitivity cardiac troponin measurements obtained at presentation and 3 hours after the initial sample as part of the conventional diagnostic strategy for suspected acute coronary syndrome.

0/1-hour high-sensitivity cardiac troponin algorithm: High-sensitivity cardiac troponin measurements obtained at presentation and 1 hour after the initial sample as part of the accelerated diagnostic strategy for suspected acute coronary syndrome.

Study summary

People with chest pain are often tested for a heart attack using a blood test called high-sensitivity cardiac troponin (hs-cTn). Traditionally, this blood test is repeated 3 hours after the first sample. Newer guidelines recommend repeating the test after 1 hour instead, which may allow patients to receive a diagnosis and leave the hospital sooner.

The purpose of the DanRUSH trial is to compare these two strategies: repeating the blood test after 1 hour versus after 3 hours in adults with suspected acute coronary syndrome. The study will evaluate whether the 1-hour strategy is as safe as the 3-hour strategy while reducing the length of hospital stay.

DanRUSH is a nationwide, pragmatic, cluster-randomized trial conducted in emergency- and cardiology departments across Denmark. The results will help determine the best timing for blood testing in patients with suspected heart attack and improve future care for these patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years) presenting with suspected acute coronary syndrome (ACS) with a clinical indication for high-sensitivity cardiac troponin testing Exclusion Criteria: * Age \<18 years. * ST-segment elevation myocardial infarction (STEMI) identified on the presenting electrocardiogram and requiring immediate reperfusion therapy.

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Aalborg University Hospital Aalborg Denmark
Bispebjerg & Frederiksberg Hospital Bispebjerg Denmark
Esbjerg og Grindsted Sygehus Esbjerg Denmark
Gødstrup Regional Hospital Gødstrup Denmark
Herlev & Gentofte Hospital Herlev Denmark
Nordsjællands Hospital Hillerød Denmark
Amager & Hvidovre Hospital Hvidovre Denmark
Nykøbing Falster County Hospital Nykøbing Falster Denmark
Odense University Hospital Odense Denmark
Svendborg Hospital Svendborg Denmark
Central Jutland Regional Hospital (Viborg Hospital & Silkeborg Hospital) Viborg Denmark

More Herlev and Gentofte Hospital trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07727135 on ClinicalTrials.gov ↗ ← All trials in Denmark